FILTER
FILTERED INTERVIEW RESULTS
Louis Lehot
MANAGING PARTNER, DLA PIPER
DLA Piper, one of the largest law firms in the world, has a footprint across 40 juris-dictions and an active life sciences sector team.
Eugene Williams
EXECUTIVE CHAIRMAN, PROMIS
ProMIS Neurosciences is a development-stage biotech company focused on neurodegenerative diseases, particularly Alzheimer’s disease and ALS.
Wu Yifang
CEO, FOSUN PHARMA
Fosun Pharma is a leading pharma company in China with innovative and global ambitions.
Sara Radcliffe
PRESIDENT & CEO, CALIFORNIA LIFE SCIENCES ASSOCIATION
California Life Sciences Association (CLSA) is the trade association representing California’s in-novative life sciences industry, ensuring that it retains its competitive edge.
Dr. Jim Li
CEO, SUNDIA
Sundia is a CRO based in China and speaks to GBR of the evolution of the drug discovery process in China.
Dr. Xu Jia
CONSULTING LEADER, PWC CHINA HEALTHCARE AND PHARMACEUTICALS
PwC in China is benefitting from the rise of the biopharma and a flurry of IPO and acquisition activities in the pharma industry more generally.
Nick Grasman
LEAD MARKET MANAGER, DOW PHARMA SOLUTIONS, THE DOW CHEMICAL COMPANY
Dow Pharma Solutions develops functional excipients and APIs that enable improved pharmaceutical delivery and enhanced solubility.
Jay Dong
GENERAL MANAGER and GLOBAL VP, CST CHINA
CST is expanding its footprint across China where R&D and innovation spending is on the rise.
Mickey Kertesz
FOUNDER & CEO, KARIUS
The Karius test harnesses next-generation sequencing to detect fragments of cell-free DNA from bacteria, viruses, fungi and protozoa that may be circulating in a patient’s bloodstream.
William Hait
GLOBAL HEAD, JOHNSON & JOHNSON GLOBAL EXTERNAL INNOVATION
Johnson & Johnson invested US$10 billion in research and development in 2017 both internally and externally.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
